BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Partners (see “Expanding Italy’s Ecosystem” ). Larry Edwards has become president and CEO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...data from the skin of psoriasis patients to predict clinical outcomes. Robin Sawka, BioCentury Staff Moderna Inc. Genespire Inc. La Jolla Pharmaceutical Co. Editas...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...Foundation Fighting Blindness’ RD Fund led the round. La Jolla completes Tetraphase takeout La Jolla Pharmaceutical Company (NASDAQ:LJPC...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...He succeeds interim CFO Eric Loumeau, who will become COO. Mulroy was CFO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...about-face this month, Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) said it will now be acquired by La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...milestones. Tetraphase will pay Melinta a $1.2 million termination fee. Elizabeth S. Eaton, Staff Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...for this population, according to the companies. Malaria drug approval sinks La Jolla shares La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...pediatric patients. La Jolla submitted an NDA to FDA in 2H19 for its IV artesunate, LJPC-0118...
...Interleukin-13 PDE-4D - Phosphodiesterase-4D S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Bristol Myers Squibb Co. Regeneron Pharmaceuticals Inc. Sanofi La Jolla Pharmaceutical Co. Shionogi...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...revealed in a regulatory filing that it has received an unsolicited acquisition offer from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Puma Biotechnology Inc. Canbridge Pharmaceuticals Inc. Tetraphase Pharmaceuticals Inc. AcelRx Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Ovid...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...deprivation therapy. La Jolla sinks as it discontinues β thalassemia trial, CEO steps down La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...NASDAQ:LJPC) lost $2.99 (54%) to $2.59 Monday after it discontinued a Phase II trial of LJPC-401...
...Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR inhibitor) LJPC-401 Global Blood Therapeutics Inc. ChemoCentryx Inc. Astellas Pharma Inc. La Jolla Pharmaceutical Co. Sorrento...
BioCentury | Aug 29, 2019
Company News

Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

...La Jolla hypotension drug approved in Europe The EC approved Giapreza angiotensin II from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Administration approved the anti-PD-1 mAb for relapsed/refractory Hodgkin lymphoma in December. Jonathan Block, Associate Editor Giapreza (Brand), LJPC-501...
...RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Tyvyt, sintilimab (IBI308) Innovent Biologics Inc. La Jolla Pharmaceutical Co. Roche...
BioCentury | Jun 28, 2019
Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

...women at high risk of fracture. CHMP backed approval of Giapreza angiotensin II from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Staff Writer biosimilar infliximab (ABP 710) Cyramza, ramucirumab (IMC-1121B, LY3009806) Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) Giapreza (Brand), LJPC-501...
...Levoglutamide (Informal), Xyndari (Informal) Translarna, ataluren (ptc124) AbbVie Inc. Amgen Inc. Eli Lilly and Co. Emmaus Life Sciences Inc. Johnson & Johnson La Jolla Pharmaceutical Co. PTC...
BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

...Among 26 patients in a Phase II trial to treat hereditary hemochromatosis, La Jolla Pharmaceutical Co. (NASDAQ:LJPC) said LJPC-401...
...ata129) LJPC-401 Ninlaro (Brand), MLN9708 (Compound #), ixazomib (Generic), Ninlaro (Other) sintilimab (IBI308) Astex Pharmaceuticals Inc. Atara Biotherapeutics Inc. Innovent Biologics Inc. La Jolla Pharmaceutical Co. Otsuka...
Items per page:
1 - 10 of 330
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...Partners (see “Expanding Italy’s Ecosystem” ). Larry Edwards has become president and CEO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...data from the skin of psoriasis patients to predict clinical outcomes. Robin Sawka, BioCentury Staff Moderna Inc. Genespire Inc. La Jolla Pharmaceutical Co. Editas...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...Foundation Fighting Blindness’ RD Fund led the round. La Jolla completes Tetraphase takeout La Jolla Pharmaceutical Company (NASDAQ:LJPC...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...He succeeds interim CFO Eric Loumeau, who will become COO. Mulroy was CFO of La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...about-face this month, Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) said it will now be acquired by La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...milestones. Tetraphase will pay Melinta a $1.2 million termination fee. Elizabeth S. Eaton, Staff Writer Tetraphase Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Melinta...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...for this population, according to the companies. Malaria drug approval sinks La Jolla shares La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...pediatric patients. La Jolla submitted an NDA to FDA in 2H19 for its IV artesunate, LJPC-0118...
...Interleukin-13 PDE-4D - Phosphodiesterase-4D S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Bristol Myers Squibb Co. Regeneron Pharmaceuticals Inc. Sanofi La Jolla Pharmaceutical Co. Shionogi...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

...revealed in a regulatory filing that it has received an unsolicited acquisition offer from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Compound #), HKI-272 (Compound #), Oral neratinib (Generic) Puma Biotechnology Inc. Canbridge Pharmaceuticals Inc. Tetraphase Pharmaceuticals Inc. AcelRx Pharmaceuticals Inc. La Jolla Pharmaceutical Co. Ovid...
BioCentury | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

...deprivation therapy. La Jolla sinks as it discontinues β thalassemia trial, CEO steps down La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...NASDAQ:LJPC) lost $2.99 (54%) to $2.59 Monday after it discontinued a Phase II trial of LJPC-401...
...Eaton, Staff Writer voxelotor (GBT440) Xtandi, enzalutamide (mdv3100, p-INN) Avacopan (CCX168, C5aR inhibitor) LJPC-401 Global Blood Therapeutics Inc. ChemoCentryx Inc. Astellas Pharma Inc. La Jolla Pharmaceutical Co. Sorrento...
BioCentury | Aug 29, 2019
Company News

Aug. 29 Company Quick Takes: EC approves Tecentriq for breast cancer, Giapreza for hypotension; plus Innovent reports Tyvyt sales

...La Jolla hypotension drug approved in Europe The EC approved Giapreza angiotensin II from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Administration approved the anti-PD-1 mAb for relapsed/refractory Hodgkin lymphoma in December. Jonathan Block, Associate Editor Giapreza (Brand), LJPC-501...
...RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Tyvyt, sintilimab (IBI308) Innovent Biologics Inc. La Jolla Pharmaceutical Co. Roche...
BioCentury | Jun 28, 2019
Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

...women at high risk of fracture. CHMP backed approval of Giapreza angiotensin II from La Jolla Pharmaceutical Co. (NASDAQ:LJPC...
...Staff Writer biosimilar infliximab (ABP 710) Cyramza, ramucirumab (IMC-1121B, LY3009806) Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) Giapreza (Brand), LJPC-501...
...Levoglutamide (Informal), Xyndari (Informal) Translarna, ataluren (ptc124) AbbVie Inc. Amgen Inc. Eli Lilly and Co. Emmaus Life Sciences Inc. Johnson & Johnson La Jolla Pharmaceutical Co. PTC...
BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

...Among 26 patients in a Phase II trial to treat hereditary hemochromatosis, La Jolla Pharmaceutical Co. (NASDAQ:LJPC) said LJPC-401...
...ata129) LJPC-401 Ninlaro (Brand), MLN9708 (Compound #), ixazomib (Generic), Ninlaro (Other) sintilimab (IBI308) Astex Pharmaceuticals Inc. Atara Biotherapeutics Inc. Innovent Biologics Inc. La Jolla Pharmaceutical Co. Otsuka...
Items per page:
1 - 10 of 330